SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Prog ...

Ozanimod showed a rapid onset of action and efficacy as extended induction therapy in patients with ulcerative colitis nonresponsive to biologics.

Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis 1. Beerse, Belgium (28 February 2025) - Johnson & Johnson today announced that the Com ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

The risk for both self-reported and symptomatic flare in inflammatory bowel disease is associated with psychosocial factors, ...

They dance in kitchens and in meadows frothy with flowers. They dance at weddings. They dance while fireworks bloom in dark ...

FAECAL microbiota transplantation (FMT) shows promise in treating ulcerative colitis (UC), with specific gut microbial ...

Reported positive interim pharmacokinetic ("PK") and safety data in Phase 1 trial of SPY001 in November 2024 and strengthened the balance sheet with a $230 million ...

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and tr ...

The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults with giant cell arteritis (GCA)1The primary endpoint ...

A new study published in BMC Gastroenterology identified that patients with inflammatory bowel disease (IBD), such as Crohn's ...